Publications

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina, VV; Filipović, SK; Kožnjak, N; Stamenić, V; CLARK, AD; Mounaud, B; Blau, J; Hoestlandt, C; Kaić, B;

2014

Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.043.

Use of vaccines as probes to define disease burden.

Feikin, DR; SCOTT, JA G; Gessner, BD;

2014

Lancet, (2014).383 9930 10.1016/S0140-6736(13)61682-7.

Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody.

Hunsperger, EA; Yoksan, S; Buchy, P; Nguyen, VC; Sekaran, SD; Enria, DA; Vazquez, S; Cartozian, E; Pelegrino, JL; Artsob, H; Guzman, MG; Olliaro, P; Zwang, J; Guillerm, M; Kliks, S; Halstead, S; PEELING, RW; Margolis, HS;

2014

PLOS NEGLECTED TROPICAL DISEASES, (2014).8 10 10.1371/journal.pntd.0003171.

Impaired natural killer cell responses to vaccine antigens in human cytomegalovirus-infected individuals.

Nielsen, CM; White, MJ; Rodriguez-Galan, A; BOTTOMLEY, C; Turner, SE G; GOODIER, MR; Riley, EM;

2014

IMMUNOLOGY, (2014).143,

Signatures of malaria vaccine efficacy in ageing murine immune memory.

Haussig, JM; Burgold, J; HAFALLA, JC R; Matuschewski, K; Kooij, TW A;

2014

Parasite immunology, (2014).36 5 10.1111/pim.12104.

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.

Christensen, H; Trotter, CL; Hickman, M; EDMUNDS, WJ;

2014

BMJ (Clinical research ed), (2014).349 oct09 10.1136/bmj.g5725.

Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".

Newall, AT; JIT, M; Hutubessy, R;

2014

PharmacoEconomics, (2014).32 12 10.1007/s40273-014-0232-0.

Age-Dependent Prevalence of Nasopharyngeal Carriage of Streptococcus pneumoniae before Conjugate Vaccine Introduction: Supporting Information.

Le Polain, O; FLASCHE, S; Prieto, D; EDMUNDS, J;

2014

, London School of Hygiene & Tropical Medicine (London, United Kingdom) (2014). 10.17037/DATA.72.

Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.

KNIGHT, GM; GRIFFITHS, UK; SUMNER, T; LAURENCE, YV; GHEORGHE, A; VASSALL, A; Glaziou, P; WHITE, RG;

2014

Proceedings of the National Academy of Sciences of the United States of America, (2014).111 43 10.1073/pnas.1404386111.

Vaccine-preventable travel health risks: what is the evidence--what are the gaps?.

Steffen, R; BEHRENS, RH; Hill, DR; Greenaway, C; Leder, K;

2014

Journal of travel medicine, (2014).22 1 10.1111/jtm.12171.